Subconjunctival Bevacizumab Injection in Treatment of Recurrent Pterygium
|Hussein Alhammami1, Qassim Farhood2* and Hassanein Shuber3|
|1FICMS, Ophthalmology Department, Medical College Kufa University, Iraq|
|2FICMS-OPH, Ophthalmology Department, Medical College, University of Babylon, Iraq|
|3FICMS, Ophthalmology Department, Medical College, Al Mustanseriah University, Iraq|
|Corresponding Author :||Qasim Kadhim Farhood
FICMS –OPH, Assistant Prof.|
Babylon University, Iraq
E-mail: [email protected]
|Received: December 09, 2012; Accepted: January 17, 2013; Published: January 23, 2013|
|Citation:Alhammami H, Farhood Q, Shuber H (2013) Subconjunctival Bevacizumab Injection in Treatment of Recurrent Pterygium. J Clin Exp Ophthalmol 4:267. doi:10.4172/2155-9570.1000267|
|Copyright: © 2013 Alhammami H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Objective: To determine the clinical effect of subconjunctival injection of bevacizumab in regression or halting growth in patients with recurrent pterygium.
Method and materials: The study was an off-label; 2-dosing, interventional case series involving 20 patients with recurrent pterygium. They received subconjunctival bevacizumab (0.2 ml/2.5 mg). Vascularity and thickness of Pterygium was graded. Size of the pterygium (measured by surface area in cm2) was recorded from baseline to 6 months, after injection. Treatment-related complications and adverse events were reported. The main outcome of measurements was the change in grading, size, vascularity, thickness and color intensity.
Results: 9 males (45%) , 11 females (55%) of 20 patients were conducted in study with a mean age of 50.46 years ± 18.30 (rang 38-70). There was a significant reduction in grading with significant difference in the mean surface area of pterygium at different intervals (P<0.05) and the size of pterygium was reduced. The reduction of color intensity was significant (P=0.031). No significant topical or systemic adverse reactions were recorded.
Conclusions: Subconjunctival bevacizumab injection is useful in management of patients with recurrent pterygium without significant local or systemic adverse effects.